Mucosal Melanoma ARTISTRY-6, Cohort 2

Phase 2

Dosing: Nemvaleukin (IV) Monotherapy (Potentially Registrational)

Anticipated Program Milestone: 
Top-line data readout expected in 1H 2025 (subject to patient enrollment)

>> Learn more about Nemvaleukin Alfa

>> Visit the ARTISTRY-6 study website